

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/186324 A1

(51) International Patent Classification:

C07D 307/81 (2006.01) C07D 407/12 (2006.01)
C07D 401/14 (2006.01) C07D 413/04 (2006.01)
C07D 403/04 (2006.01) C07D 417/04 (2006.01)
C07D 405/04 (2006.01) C07D 491/04 (2006.01)
C07D 405/10 (2006.01) A61P 35/00 (2006.01)
C07D 405/12 (2006.01) A61K 31/343 (2006.01)
C07D 405/14 (2006.01) A61K 31/443 (2006.01)
C07D 407/04 (2006.01)

(21) International Application Number:

PCT/IB2021/052136

(22) International Filing Date:

15 March 2021 (15.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20163465.6 16 March 2020 (16.03.2020) EP
PCT/CN2021/075550
05 February 2021 (05.02.2021) CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BORDAS, Vincent**; c/o Novartis Pharma AG,
Postfach, 4002 Basel (CH). **BROCKLEHURST, Cara**; c/o
Novartis Pharma AG, Postfach, 4002 Basel (CH). **CH-
ENE, Patrick**; c/o Novartis Pharma AG, Postfach, 4002
Basel (CH). **FEI, Zhongbo**; c/o Suzhou Novartis Techni-
cal Development Co., LTD., No. 18-1 Tonglian Road, Bixi
Subdistrict, Changshu City, Jiangsu 215537 (CN). **FURET, Pascal**;
c/o Novartis Pharma AG, Postfach, 4002
Basel (CH). **GUAGNANO, Vito**; c/o Novartis Pharma AG,
Postfach, 4002 Basel (CH). **IMBACH-WEESE, Patricia**;
Oberschels Feld 4, 33739 Bielefeld (DE). **KALLEN,
Joerg**; Kaltbrunnenstrasse 41, 4054 Basel (CH). **LE
DOUGET, Mickael**; c/o Novartis Pharma AG, Postfach,
4002 Basel (CH). **LI, Jialiang**; c/o Suzhou Novartis Techni-
cal Development Co., LTD., No. 18-1 Tonglian Road, Bixi
Subdistrict, Changshu, Jiangsu 215537 (CN). **LI, Wei**; c/o
Suzhou Novartis Technical Development Co., LTD., No.
18-1 Tonglian Road, Bixi Subdistrict, Changshu, Jiangsu
215537 (CN). **LORTHIOIS, Edwige Liliane Jeanne**; c/o
Novartis Pharma AG, 4002 Basel (CH). **MCKENNA,
Joseph**; c/o Novartis Pharma AG, Postfach, 4002 Basel
(CH). **SALEM, Bahaa**; c/o Novartis Pharma AG, Postfach,

4002 Basel (CH). **SCHMELZLE, Tobias**; c/o Novartis
Pharma AG, Postfach, 4002 Basel (CH). **SELLNER, Hol-
ger**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).
SOLDERMANN, Nicolas; c/o Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **VOEGTLE, Markus**; c/o Novartis
Pharma AG, Postfach, 4002 Basel (CH). **WARTMANN,
Markus**; c/o Novartis Pharma AG, Postfach, 4002 Basel
(CH).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS



(57) Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

WO 2021/186324 A1